Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22079961 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)
Condition: Central Serous Chorioretinopathy
Interventions: Device: subthreshold micropulselaser;   Drug: bevacizumab

Indicates status has not been verified in more than two years